Elicio Therapeutics, Inc.
ELTX•NASDAQ•Healthcare•Biotechnology

About Elicio Therapeutics

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEORobert Connelly
Founded2011
Employees32
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websiteelicio.com
Phone857 209 0050
Address
451 D Street, 5th Floor Boston, Massachusetts 02210 United States

Corporate Identifiers

CIK0001555192
CUSIP28657F103
ISINUS28657F1030
EIN45-2966790
SIC2834

Leadership Team & Key Executives

Robert T. Connelly
Chief Executive Officer, President and Director
Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D.
Founder and Independent Director
Dr. Peter DeMuth Ph.D.
Chief Scientific Officer
Dr. Christopher M. Haqq M.D., Ph.D.
Executive Vice President, Head of Research and Development and Chief Medical Officer
Dr. Darrell J. Irvine Ph.D.
Co-Founder, Consultant, Board Observer and Chairman of Scientific Advisory Board
Dr. Preetam Shah M.B.A., Ph.D.
Chief Strategy and Financial Officer and Treasurer
Marc J. Wolfgang M.S.
Chief Technology Officer
Megan C. Filoon
General Counsel, Secretary and Compliance Officer
Esther Welkowsky
Senior Vice President of Clinical Development
Joy Seymour
Vice President and Head of Regulatory Affairs